Cancer Medicine (Jan 2020)

Advances in IKBKE as a potential target for cancer therapy

  • Min Yin,
  • Xin Wang,
  • Jie Lu

DOI
https://doi.org/10.1002/cam4.2678
Journal volume & issue
Vol. 9, no. 1
pp. 247 – 258

Abstract

Read online

Abstract IKBKE (inhibitor of nuclear factor kappa‐B kinase subunit epsilon), a member of the nonclassical IKK family, plays an important role in the regulation of inflammatory reactions, activation and proliferation of immune cells, and metabolic diseases. Recent studies have demonstrated that IKBKE plays a crucial regulatory role in malignant tumor development. In recent years, IKBKE, an important oncoprotein in several kinds of tumors, has been widely found to regulate a variety of cytokines and signaling pathways. IKBKE promotes the growth, proliferation, invasion, and drug resistance of various cancers. This paper makes a detailed review that focuses on the recent discoveries of IKBKE in the malignant tumors, and puts forward that IKBKE is becoming an important therapeutic target for clinical treatment, which has been more and more realized.

Keywords